Record-Breaking Price Movement
On 8 April 2026, Venus Remedies Ltd's stock surged to an intraday high of ₹947, marking its highest-ever trading price. This peak is just 0.58% shy of the 52-week high of ₹950, underscoring the stock's strong upward trajectory. The stock closed with a day gain of 2.29%, aligning closely with the sector's performance. Notably, Venus Remedies is trading above all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling a sustained bullish trend.
Impressive Relative Performance Against Benchmarks
Venus Remedies has outperformed the broader market indices over multiple time horizons. Its one-year return stands at an exceptional 217.25%, vastly exceeding the Sensex's 4.09% gain over the same period. Year-to-date, the stock has appreciated by 23.14%, while the Sensex has declined by 9.34%. Over three years, Venus Remedies has delivered a remarkable 442.48% return compared to the Sensex's 29.13%. Even over a decade, the stock's growth of 949.39% dwarfs the Sensex's 213.14%, highlighting its long-term value creation.
Financial Strength and Quality Metrics
The company’s financial health is reflected in its low debt profile, with an average Debt to Equity ratio of zero, indicating a net cash position. Venus Remedies boasts a strong operating profit growth of 96.37% as of December 2025, supported by five consecutive quarters of positive results. The company’s Return on Capital Employed (ROCE) reached a high of 13.99% in the half-year period, while the Inventory Turnover Ratio peaked at 6.58 times, signalling efficient asset utilisation.
Quarterly financials further reinforce the company’s robust performance, with the highest recorded PBDIT at ₹37.52 crores and a quarterly PAT of ₹25.58 crores. Earnings per share (EPS) for the quarter stood at ₹19.13, underscoring profitability gains. The Price to Book Value ratio of 2.07x and a Price to Earnings (P/E) ratio of 16x reflect a fair valuation relative to its earnings and book value.
Valuation and Market Capitalisation
Venus Remedies is classified as a micro-cap company, with valuation multiples indicating reasonable pricing. The EV/EBITDA ratio is 8.92x, and the EV/EBIT stands at 11.28x, suggesting moderate enterprise value relative to earnings. The PEG ratio of 0.09x highlights the stock’s attractive valuation in relation to its earnings growth, which has risen by 182.3% over the past year. The company declared a dividend of ₹3 per share, with the last ex-dividend date recorded in September 2013.
Technical Analysis Confirms Bullish Momentum
The technical outlook for Venus Remedies remains strongly positive. The overall trend shifted to bullish on 12 March 2026 at a price of ₹927.5, supported by bullish signals from MACD, Bollinger Bands, and On-Balance Volume (OBV) indicators on both weekly and monthly charts. Moving averages also confirm the upward momentum. Immediate support is established at the 52-week low of ₹277.85, while resistance levels are noted at ₹863.65 (20-day moving average) and the 52-week high of ₹950.
Delivery volumes have surged significantly, with a 1-month delivery change of 1998.3% and a 1-day delivery increase of 47.04% compared to the 5-day average, indicating strong investor participation in recent trading sessions.
Institutional Participation and Shareholding Trends
Institutional investors have increased their stake by 0.67% over the previous quarter, now collectively holding 3.28% of the company’s shares. This growing institutional interest reflects confidence in the company’s fundamentals and financial discipline, given their superior resources for company analysis.
Long-Term Growth and Quality Assessment
While Venus Remedies has demonstrated exceptional short- and medium-term growth, its long-term sales growth rate over five years stands at a modest 6.29% annually. The company maintains an average quality grade, with excellent capital structure and strong interest coverage ratios. It operates with zero promoter share pledging and a strong balance sheet, further enhancing its financial stability.
Return on Equity (ROE) and Return on Capital Employed (ROCE) averages are moderate at 7.52% and 7.85%, respectively, reflecting steady but cautious capital efficiency. The company’s EBIT growth over five years is a more encouraging 29.54%, indicating improving operational profitability.
Summary of Key Financial and Market Metrics as of 8 April 2026
Price: ₹944.45
52-Week Range: ₹277.85 – ₹950.00
Market Cap Grade: Micro-cap
Mojo Score: 74.0 (Buy Grade, upgraded from Hold on 12 March 2026)
P/E Ratio (TTM): 16x
Price to Book Value: 2.07x
PEG Ratio: 0.09x
Dividend: ₹3 per share (last ex-dividend Sep 2013)
Day’s High: ₹947 (2.56% increase)
Day Change: 2.29%
1 Year Return: 217.25%
3 Year Return: 442.48%
5 Year Return: 228.16%
10 Year Return: 949.39%
Venus Remedies Ltd’s achievement of an all-time high price is a testament to its consistent financial performance, operational efficiency, and strong market positioning within the Pharmaceuticals & Biotechnology sector. The stock’s sustained outperformance relative to benchmark indices and peers highlights its significant value creation over both short and long-term horizons.
